|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
86618 JD HEALTH-R
Nominal 
31.000 -0.550 (-1.743%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 58,159,881 | 8.649% | 53,529,941 | 46,736,150 | 30,682,267 | 19,382,568 |
| Cost of Sales | (44,851,304) | 7.648% | (41,664,605) | (36,844,642) | (23,484,985) | (14,465,270) |
| Gross Profit | 13,308,577 | 12.164% | 11,865,336 | 9,891,508 | 7,197,282 | 4,917,298 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (315,853) | 352.129% | (69,859) | (98,202) | (38,352) | (17,539,975) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (85,527) | 20.874% | (70,757) | (96,759) | (94,165) | (77,024) | |
| Profit / (Loss) before Taxation | 4,796,676 | 78.093% | 2,693,348 | 695,809 | (901,491) | (17,072,141) | |
| Taxation | (639,662) | 16.203% | (550,468) | (312,580) | (171,327) | (162,756) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 4,830 | -- | (1,039) | (3,124) | (689) | 534 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 4,161,844 | 94.312% | 2,141,841 | 380,105 | (1,073,507) | (17,234,363) | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (1,952,308) | 0.658% | (1,939,547) | (855,167) | (451,570) | (145,700) |
| Depreciation & Amortisation | 214,695 | -5.611% | 227,458 | 140,676 | 63,169 | 27,221 |
| Directors' Emoluments | -- | -- | 418,439 | 664,846 | 1,062,758 | 296,370 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 132.000 | 91.304% | 69.000 | 12.000 | -35.000 | -780.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 1.474 | 1.901 | 1.109 | 1.675 |
| NBV per share ($) | 17.267 | -- | 15.479 | 14.082 | 12.475 | 12.326 |
| Remarks: | Real time quote last updated: 13/03/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 4,161,844 |
| %Change | 94.312% |
| EPS / (LPS) | RMB 1.320 |
| NBV Per Share (¥) | RMB 17.267 |